Hyperfine (HYPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, to be held virtually via live audio webcast.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of five directors: Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Hyperfine
- Q2 2026 revenue up 45% YoY, margin above 50%, and strong global adoption outlook.HYPR
Q2 2026 - Portable MRI innovation fuels rapid growth, clinical adoption, and global expansion.HYPRJefferies Global Healthcare Conference 2026
- Directors and auditor ratified; no shareholder questions; all proposals approved.HYPRAGM 2026
- Up to 1,083,335 shares registered for resale, with proceeds from warrant exercises funding operations.HYPRRegistration filing
- Q1 2026 revenue surged 83% to $3.9M, margin hit 51%, and cash runway extends into 2028.HYPRQ1 2026
- Director elections, auditor ratification, and executive pay updates under controlled company governance.HYPRProxy filing
- Q4 2025 revenue up 128% year-over-year; 2026 guidance targets 55% growth and margin gains.HYPRQ4 2025
- Record Q2 revenue, raised 2024 guidance, and global expansion signal accelerating growth.HYPRQ2 2024
- Portable AI-powered brain MRI drives growth and expands access in neurology care.HYPRJefferies Global Healthcare Conference